Nye behandlingsmuligheder ved primær immun trombocytopeni

Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, Claus Henrik Nielsen, Ove Juul Nielsen, Jesper Stentoft, Hans Carl Hasselbalch

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.
TidsskriftUgeskrift for Laeger
Udgave nummer4
Sider (fra-til)271-4
Antal sider4
StatusUdgivet - 2011



  • Antibodies, Monoclonal, Murine-Derived
  • Benzoic Acids
  • Dexamethasone
  • Glucocorticoids
  • Humans
  • Hydrazines
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Prednisolone
  • Purpura, Thrombocytopenic, Idiopathic
  • Pyrazoles
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Splenectomy
  • Thrombopoietin


Gudbrandsdottir, S., Frederiksen, H., Birgens, H. S., Nielsen, C. H., Nielsen, O. J., Stentoft, J., & Hasselbalch, H. C. (2011). Nye behandlingsmuligheder ved primær immun trombocytopeni. Ugeskrift for Laeger, 173(4), 271-4.